Pseudobase Benzo[c]phenanthridines Prodrug Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current benzo[c]phenanthridinium alkaloids face limitations in pharmacological efficacy due to their lipophilicity and stability issues, which affect their ability to target specific sites within the body, leading to reduced efficacy and increased toxicity.
Innovation Solution
Development of pseudobase benzo[c]phenanthridines, which act as prodrugs that can selectively target hydrophilic or hydrophobic regions, facilitating passive diffusion across cell membranes and converting back to the parent alkaloid at the site of action, thereby enhancing efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If benzo[c]phenanthridinium alkaloids are used to treat diseases, then they exhibit strong cytotoxic activity and anti-microbial properties, but they show increased toxicity and reduced safety due to their inherent chemical reactivity and instability
Solution Approach 1:
The patent divides the single active compound into two separate components: a stable pseudobase prodrug and a targeting agent (such as a cell-penetrating peptide or antibody). The pseudobase itself is unstable and reactive, but when conjugated to the targeting agent, it becomes stable and can be delivered specifically to the target site, reducing systemic toxicity while maintaining therapeutic efficacy.
Solution Approach 2:
The patent introduces a targeting agent as an intermediary between the pseudobase prodrug and the target site. This intermediary guides the prodrug to specific cells or tissues (such as cancer cells or microbial sites) and facilitates controlled release of the active alkaloid at the target site, thereby enhancing efficacy while minimizing off-target toxicity.
2Ease of operation
If pseudobase benzo[c]phenanthridines are designed to improve membrane permeability, then they can better target hydrophobic regions, but they may lose selectivity and accumulate in non-target tissues
Solution Approach 1:
The patent merges the pseudobase prodrug with a targeting agent (such as a cell-penetrating peptide or antibody) to create a conjugate that combines the membrane-permeable properties of the pseudobase with the target-specific recognition capabilities of the targeting agent. This ensures both improved permeability and maintained selectivity.
Solution Approach 2:
The patent employs targeting agents that provide feedback mechanisms for controlled release. The pseudobase is released only when specific conditions are met at the target site (such as specific pH levels, enzymatic activity, or cellular uptake mechanisms), ensuring that the active compound is activated only where needed and not in non-target tissues.
3Reliability
If the quaternary nitrogen is maintained to preserve pharmacological activity, then the compound shows strong anti-microbial and anti-cancer effects, but it creates inherent chemical reactivity and stability issues
Solution Approach 1:
The patent performs preliminary action by converting the unstable, highly reactive quaternary nitrogen alkaloid into a stable pseudobase prodrug before administration. The pseudobase form is chemically stable and can be stored and administered safely. Upon reaching the target site, the pseudobase is converted back to the active quaternary nitrogen form through physiological processes such as enzymatic hydrolysis or pH-dependent conversion, thereby preserving pharmacological activity while ensuring stability during storage and transport.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Pseudobase benzo[c]phenanthridines demonstrate improved cell membrane permeability and selectivity, leading to increased potency and reduced toxicity, effectively targeting microbial infections, cancer, and other diseases while minimizing adverse effects.
Implementation Method 1
facilitating passive diffusion across cell membranes
Data Source
AI summary
Pseudobase benzo[c]phenanthridines and the pharmaceutically acceptable salts thereof of Formula Iare provided herein. The variables R, R1, R2, R3, and R4 are defined herein. Certain pseudobase benzo[c]phenanthridines provided herein act as prodrugs, targeting the parent benzo[c]phenanthridinium alkaloid to hydrophilic or hydrophobic regions in the body. Pharmaceutical compositions comprising a pseudobase benzo[c]phenanthridine and a carrier, excipient, or diluent are provided herein. Methods of treating or preventing microbial, fungal and or viral infections and methods of treating diseases and disorders responsive to protein kinase C modulation, topoisomerase I, and/or topoisomerase II modulation are also provided.